YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017

This table browses all dspace content
Issue Date	Title	Journal Title
2025	Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients	KOREAN CIRCULATION JOURNAL
2025	Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A	JOURNAL OF THORACIC ONCOLOGY
2025	Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease	GUT AND LIVER
2025	Differences in risk factors associated with the initiation and progression of mitral annular calcification in asymptomatic individuals	SCIENTIFIC REPORTS
2025	Childhood trauma is associated with perceived stress and hair cortisol levels characterized by the BDNF Val66Met genotype and sex	FRONTIERS IN PSYCHIATRY
2025	Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)	INFECTIOUS DISEASES AND THERAPY
2025	Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study	ARTHRITIS RESEARCH & THERAPY
2025	Association of Extended Steroid Treatment With Bloodstream Infection in Critically Ill Patients With COVID-19: A National, Multicenter, Propensity Score-Matched Study	JOURNAL OF KOREAN MEDICAL SCIENCE
2025	Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA	FUTURE ONCOLOGY
2025	Metabolic Status and Atrioventricular Block Risk: The Role of Physical Activity	REVIEWS IN CARDIOVASCULAR MEDICINE
2025	Integration of Left Atrial Function Assessment, Genetic Risk, and Clinical Risk Factors Improves Prediction of Incident Atrial Fibrillation	JOURNAL OF THE AMERICAN HEART ASSOCIATION
2025	Connection between Impaired Fasting Glucose or Type 2 Diabetes Mellitus and Sepsis: A 10-Year Observational Data from the National Health Screening Cohort	DIABETES & METABOLISM JOURNAL
2025	Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	BRITISH JOURNAL OF CANCER
2025	Disagreement on estimating cause of death under tuberculosis treatment between the national tuberculosis registry and statistics data in South Korea, 2011-2020	JOURNAL OF INFECTION AND PUBLIC HEALTH
2025	Dynamic Response of Musclin, a Myokine, to Aerobic Exercise and Its Interplay With Natriuretic Peptides and Receptor C	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2025	One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study	INFLAMMATORY BOWEL DISEASES
2025	Peripherally induced RORγt+ skin-resident regulatory T cells mediate the efficacy of allergen-specific immunotherapy	SCIENCE TRANSLATIONAL MEDICINE
2025	Microarray Patch Based Transdermal Allergen Immunotherapy Prevents Gliadin-induced Anaphylaxis in a Murine Model	ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
2025	Metabolic Disorders and Inflammatory Bowel Diseases	GUT AND LIVER
2025	Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib	ANNALS OF ONCOLOGY